Abstract
Bullous pemphigoid (BP) and psoriasis are common immune-related dermatosis. The concurrence of these two diseases is rare. The coexistence of the two conditions imposes a difficult therapeutic challenge. We reported a case of concurrence of BP and psoriasis vulgaris which was successfully treated by abrocitinib. Based on our research, abrocitinib appears to be an effective and safe therapeutic option for patients with concurrent BP and psoriasis.